Could this be the secret to Pfizer's rebound strategy?

It could prove to be a case of better later than never for the healthcare giant.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.

Futures are trading higher as we get ready to start the first full week of trading for the third quarter, as traders and ...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...